StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a report published on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
Genocea Biosciences has a one year low of $0.00 and a one year high of $0.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35. The company has a market cap of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61.
About Genocea Biosciences
Read More
- Five stocks we like better than Genocea Biosciences
- What Are the FAANG Stocks and Are They Good Investments?
- MarketBeat Week in Review – 4/22 – 4/26
- How to Invest in the Best Canadian Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Use the MarketBeat Excel Dividend Calculator
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.